PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

Heather Oakervee, Rakesh Popat, Nicola Curry, +8

British Journal of Haematology

Relapsed Multiple MyelomaImmunologyPharmacotherapyMyeloid NeoplasiaHematological Malignancy +15

Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres

P Windrum, T. C. M. Morris, Mary Drake, +2

Bone Marrow Transplantation

Regenerative MedicineTranslational MedicineTransplantationMarrow TransplantationMedicine +11

Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up

Rakesh Popat, Heather Oakervee, Simon Hallam, +7

British Journal of Haematology

Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system

Mary Drake, Lisa Ranaghan, T. C. M. Morris, +6

British Journal of Haematology

Efficacy and outcome of autologous transplantation in rare myelomas

Curly Morris, Mary Drake, Jane F. Apperley, +9

Haematologica

Benefit and Timing of Second Transplantations in Multiple Myeloma: Clinical Findings and Methodological Limitations in a European Group for Blood and Marrow Transplantation Registry Study

Curly Morris, S. Iacobelli, R. Brand, +4

Journal of Clinical Oncology

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Rakesh Popat, Heather Oakervee, Nicola Curry, +8

Blood

Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim

Christine Macartney, Elizabeth Burke, J.S. Elborn, +6

Leukemia & lymphoma/Leukemia and lymphoma

Tracheobronchitis52-Year-old GentlemanPneumothoraxRespiratory DiseasesPathology +8

Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression

Christine Matthews, Mark Catherwood, T. C. M. Morris, +4

European Journal Of Haematology

Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma

T. C. M. Morris, Paul Kettle, Mary Drake, +7

British Journal of Haematology

Hematological MalignancyRelapsed/refractory MyelomaAntibioticsClarithromycin 250Medicine +12